The report pertains to phosphorous acid, triphenyl ester (synonym: triphenyl phosphite) (CAS No. 101-02-0) and is being submitted because of lethality with central nervous system signs observed in an acute intraperitoneal study in cats, decreased cholinesterase activity observed in an acute intraperitoneal toxicity study in mice, and effects observed in a dermal sensitization study in guinea pigs. The intraperitoneal LD, was less than 100 mg/kg in cats. Intraperitoneal injection of 100 mg/kg and 1,000 mg/kg in mice decreased cholinesterase levels by 20 and 43%, respectively. Abnormalities observed during a dermal sensitization study in guinea pigs included bruising of the skin from touching or handling, suggesting cataneous capillary fragility. The report is being identified as a study involving other than human effects (Unit II.B.2.b of CAP Agreement).